FTC OKs $500M Valeant-PreCision Deal With Acne Drug Sales
The Federal Trade Commission agreed Thursday to sign off on Valeant Pharmaceutical International Inc.'s $500 million acquisition of PreCision Dermatology Inc. on the condition that the companies sell the rights to...To view the full article, register now.
Already a subscriber? Click here to view full article